From: Erythropoiesis: insights into pathophysiology and treatments in 2017
Company | Drug | Mechanism | Eligibility | Route | Clintrials.gov | Status |
---|---|---|---|---|---|---|
Small molecules targets | ||||||
Incyte Coproration Novartis | Jak 1/2 inhibitor (ruxolitinib) vs BAT | Cytoreduction | - age ≥ 18 years | Oral | NCT01243944 |
Active, not recruiting - Phase 3 |
Incyte | Jak 1/2 inhibitor (ruxolitinib) vs HU | Cytoreduction | - age ≥ 18 years | Oral | NCT01632904 |
Completed - Phase 3 |
AOP Orphan Pharmaceuticals AG | Pegylated interferon alpha-2b (AOP2014) vs HU | Cytoreduction | - age ≥ 18 years | subcutaneously | NCT01949805 |
Completed - Phase 3 |
Roskilde University Hospital, | Vorinostat | Cytoreduction | - age ≥ 18 years | Oral | – |
Completed - Phase 2 |
Italframaco | Givinostat vs HU | Cytoreduction | - age ≥ 18 years | Oral | NCT00928707 |
Completed - Phase 2 |